Similarly, patients with unresectable stage III NSCLC may receive consolidation treatment with durvalumab, a PD-L1 inhibitor, after chemoradiotherapy, for which the European Society for Medical Oncology (ESMO) recommended that patients should have a PD-L1 expression of at least 1% on tumor cells [7]. The gene discussed is CD274; the disease is neoplasm.